Anne-Marie Mes-Masson

Dr. Mes-Masson trained as a molecular oncologist, and obtained her Ph.D. from the Department of Microbiology and Immunology at McGill University in 1984. From 1984-1986, she completed post-doctoral studies at the Molecular Biology Institute, University of California Los Angeles, in the laboratory of Dr. Owen Witte where she was the first to clone the full length BCR-ABL transcript implicated in Chronic Myelogenous Leukemia. After a short period as a research associate at the Biotechnology Research Institute, Dr Mes-Masson joined the Institut du cancer de Montréal and the Department of Medicine at the Université de Montréal in 1989. A full professor since 2001, Dr. Mes-Masson was the scientific director of the Institut du cancer de Montréal and Director of cancer research at the Centre de recherche du Centre hospitalier de l’université de Montréal (CRCHUM) from 2003-2018 and in 2017 accepted the position of Associate Director, Basic and Translational Research, at the CRCHUM. In 2003, Dr. Mes-Masson was named the Director of the Réseau de recherche sur le cancer du Fonds de recherche du Québec - Santé (FRQS), a provincial cancer network of over 100 scientists focused on translational and clinical cancer research (www.rrcancer.ca). Dr. Mes-Masson is a founding member of the Canadian Tumor Repository Network that focuses on enhancing capacity and quality of biobanking to support research (www.ctrnet.ca). In 2008 Dr. Mes-Masson was named the Quebec node coordinator for the Terry Fox Research Institute (TFRI).

Dr. Mes-Masson has authored over 250 publications in cancer research. In addition to her pioneering work in biobanking, the major focus over her research in the last three decades has been ovarian and prostate cancer. While maintaining an active basic research program that focuses on the molecular events that contribute to cancer initiation and progression. Dr. Mes-Masson has also established a translational research program largely focused on delivering personalized medicine in oncology. Her recent fundamental research focuses on the prediction of therapeutic responses and the development of new therapeutic agents for ovarian and prostate cancers.